Literature DB >> 23444214

Zoom Zoom: racing CARs for multiple myeloma.

Marcela V Maus1, Carl H June.   

Abstract

Chimeric antigen receptors redirect T cells to surface antigens. Discovery and validation of appropriate target antigens expand the possible indications for chimeric-antigen receptor (CAR)-T cells. B-cell maturation antigen (BCMA) is expressed only on mature B cells and plasma cells and promotes their survival. BCMA is a promising target for CAR-T cells in multiple myeloma.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23444214      PMCID： PMC3630266          DOI： 10.1158/1078-0432.CCR-13-0168

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

Authors:  James N Kochenderfer; Mark E Dudley; Steven A Feldman; Wyndham H Wilson; David E Spaner; Irina Maric; Maryalice Stetler-Stevenson; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; James C Yang; Udai S Kammula; Laura Devillier; Robert Carpenter; Debbie-Ann N Nathan; Richard A Morgan; Carolyn Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

2.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

Authors:  Brian G Till; Michael C Jensen; Jinjuan Wang; Xiaojun Qian; Ajay K Gopal; David G Maloney; Catherine G Lindgren; Yukang Lin; John M Pagel; Lihua E Budde; Andrew Raubitschek; Stephen J Forman; Philip D Greenberg; Stanley R Riddell; Oliver W Press
Journal:  Blood       Date:  2012-02-03       Impact factor: 22.113

3.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors:  David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

4.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

5.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

Authors:  Cor H J Lamers; Stefan Sleijfer; Arnold G Vulto; Wim H J Kruit; Mike Kliffen; Reno Debets; Jan W Gratama; Gerrit Stoter; Egbert Oosterwijk
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

Review 6.  Regulatory roles of the tumor necrosis factor receptor BCMA.

Authors:  Christine M Coquery; Loren D Erickson
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

7.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

Authors:  Chrystal U Louis; Barbara Savoldo; Gianpietro Dotti; Martin Pule; Eric Yvon; G Doug Myers; Claudia Rossig; Heidi V Russell; Oumar Diouf; Enli Liu; Hao Liu; Meng-Fen Wu; Adrian P Gee; Zhuyong Mei; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal:  Blood       Date:  2011-10-07       Impact factor: 22.113

8.  B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus.

Authors:  Chao Jiang; William M Loo; Erin J Greenley; Kenneth S Tung; Loren D Erickson
Journal:  J Immunol       Date:  2011-05-02       Impact factor: 5.422

9.  APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.

Authors:  Jérôme Moreaux; Anne-Catherine Sprynski; Stacey R Dillon; Karène Mahtouk; Michel Jourdan; Arnaud Ythier; Philippe Moine; Nicolas Robert; Eric Jourdan; Jean François Rossi; Bernard Klein
Journal:  Eur J Haematol       Date:  2009-05-30       Impact factor: 2.997

10.  BCMA is essential for the survival of long-lived bone marrow plasma cells.

Authors:  Brian P O'Connor; Vanitha S Raman; Loren D Erickson; W James Cook; Lehn K Weaver; Cory Ahonen; Ling-Li Lin; George T Mantchev; Richard J Bram; Randolph J Noelle
Journal:  J Exp Med       Date:  2004-01-05       Impact factor: 14.307
View more
  16 in total

Review 1.  Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.

Authors:  Matthew Ho Zhi Guang; Amanda McCann; Giada Bianchi; Li Zhang; Paul Dowling; Despina Bazou; Peter O'Gorman; Kenneth C Anderson
Journal:  Leuk Lymphoma       Date:  2017-06-13

2.  Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

Authors:  Yu-Tzu Tai; Patrick A Mayes; Chirag Acharya; Mike Y Zhong; Michele Cea; Antonia Cagnetta; Jenny Craigen; John Yates; Louise Gliddon; William Fieles; Bao Hoang; James Tunstead; Amanda L Christie; Andrew L Kung; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2014-02-25       Impact factor: 22.113

3.  Promising therapies in multiple myeloma.

Authors:  Giada Bianchi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

4.  BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.

Authors:  Shih-Feng Cho; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Ann Transl Med       Date:  2018-12

Review 5.  Allogeneic stem cell transplantation for multiple myeloma: is there a future?

Authors:  B Dhakal; D H Vesole; P N Hari
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

Review 6.  The development of potential antibody-based therapies for myeloma.

Authors:  Daniel W Sherbenou; Christopher R Behrens; Yang Su; Jeffrey L Wolf; Thomas G Martin; Bin Liu
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

Review 7.  Cellular and vaccine immunotherapy for multiple myeloma.

Authors:  Alfred L Garfall; Edward A Stadtmauer
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 8.  Targeting B-cell maturation antigen in multiple myeloma.

Authors:  Yu-Tzu Tai; Kenneth C Anderson
Journal:  Immunotherapy       Date:  2015-09-15       Impact factor: 4.196

9.  The vigor of defense against non-self: potential superiority of allorestricted T cells in immunotherapy of cancer?

Authors:  Stefan Burdach; Hans-Jochem Kolb
Journal:  Front Oncol       Date:  2013-05-03       Impact factor: 6.244

10.  CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.

Authors:  J Chu; Y Deng; D M Benson; S He; T Hughes; J Zhang; Y Peng; H Mao; L Yi; K Ghoshal; X He; S M Devine; X Zhang; M A Caligiuri; C C Hofmeister; J Yu
Journal:  Leukemia       Date:  2013-09-26       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.